Clinical Trial News and Research

RSS

PLC Systems reports total revenues of $1,062,000 for first-quarter 2010

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three-month period ended March 31, 2010.

14 May 2010

Phase 2a study results of Aerosurf for prevention of RDS in premature infants published

Discovery Laboratories, Inc., announces the publication of results from its previously-conducted Phase 2a feasibility study of Aerosurf, the Company's aerosolized KL4 surfactant, for the prevention of respiratory distress syndrome in premature infants, in the May 2010 issue of the Journal of Aerosol Medicine and Pulmonary Drug Delivery in the study titled "An Open Label, Pilot Study of Aerosurf Combined with nCPAP to Prevent RDS in Preterm Neonates".

14 May 2010

EPA continues to validate ToxCast screening tool by testing more than 100 drugs

The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.

14 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

FREEDOM trial results to be presented at Heart Rhythm 2010

St. Jude Medical, Inc., a global medical device company, today announced results of the FREEDOM trial during the late breaking clinical trial presentations at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions. The trial demonstrated that the QuickOpt optimization feature available in St. Jude Medical cardiac resynchronization therapy devices produces an equivalent response rate in CRT patients as optimization using echocardiography.

14 May 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable genetic disease called familial adenomatous polyposis.

14 May 2010

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.

14 May 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

Smoking, obesity and alcohol use associated with poorer survival of non-Hodgkin's lymphoma patients

A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors.

14 May 2010

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2010.

14 May 2010

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

14 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

Study results of Cameron Health's S-ICD- System published online in NEJM

Cameron Health, Inc. today announced the publication of study results online in the New England Journal of Medicine highlighting the development and potential benefits of the company's S-ICD- System, the first minimally invasive, subcutaneous implantable cardioverter defibrillator, for the treatment of sudden cardiac arrest.

14 May 2010

Nephros reports 57% increase in revenues for first-quarter 2010

Nephros, Inc. announced today financial results for the three months ended March 31, 2010.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

ARYx Therapeutics, Inc. today reported results of operations and provided an update on its business activities for the first quarter ended March 31, 2010.

13 May 2010

Genta first-quarter net loss increases to $166.6 million

Genta Incorporated today announced financial results for the quarter ended March 31, 2010.

13 May 2010

Clinical Trial News and Research

PLC Systems reports total revenues of $1,062,000 for first-quarter 2010

Phase 2a study results of Aerosurf for prevention of RDS in premature infants published

EPA continues to validate ToxCast screening tool by testing more than 100 drugs

Inhibitex reports net loss of $4.8M for first-quarter 2010

FREEDOM trial results to be presented at Heart Rhythm 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Smoking, obesity and alcohol use associated with poorer survival of non-Hodgkin's lymphoma patients

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

Study results of Cameron Health's S-ICD- System published online in NEJM

Nephros reports 57% increase in revenues for first-quarter 2010

Chimerix commences first-in-human study of CMX157 for HIV

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

Genta first-quarter net loss increases to $166.6 million

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer